Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q3 2022 · 10-Q
Revenue$11.41M$11.41M+41.4% vs Q3 2021 Net Income-$408.64K-$408.64KN/M vs Q3 2021 EPS Diluted-$0.03-$0.03N/M vs Q3 2021 Operating Income-$288,588N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$2,543,892N/M Margins · derivedOperating margin-2.5%+16.8 pt vs Q3 2021
Net margin-3.6%+9.5 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 14, 2022 · 45 d after period end